| Prev Close | 46.44 |
| Open | 46.39 |
| Day Low/High | 46.39 / 46.90 |
| 52 Wk Low/High | 12.56 / 29.81 |
| Volume | 11.68M |
| Avg Volume | 2.77M |
Latest News
Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
Pfizer To Acquire Array BioPharma
- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
Pfizer To Acquire Array BioPharma
Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)
Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.
Array BioPharma To Present At The Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma Inc.
Array BioPharma To Present At The Jefferies 2019 Global Healthcare Conference
BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc.
Array BioPharma Announces Presentation Of Updated Overall Survival From The Phase 3 COLUMBUS Trial Of BRAFTOVI MEKTOVI In Advanced BRAF-mutant Melanoma At 2019 ASCO Annual Meeting
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months -
Array BioPharma Announces BRAFTOVI MEKTOVI Cetuximab Meet Primary Endpoints Of ORR And OS In Phase 3 BEACON CRC Trial Interim Analysis For The Treatment Of BRAF(V600E)-mutant Metastatic Colorectal Cancer
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control -
Array BioPharma To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference
BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2019
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter -
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2019 On May 7, 2019
BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
BRAFTOVI® (encorafenib) In Combination With MEKTOVI® (binimetinib) And ERBITUX® (cetuximab) Or Panitumumab Recommended By The National Comprehensive Cancer Network® (NCCN) Guidelines As A Treatment Option For Patients With Advanced BRAF-mutant Colorectal Cancer
BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc.
Array BioPharma To Present At The 39th Annual Cowen Health Care Conference
BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array BioPharma Inc.
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Array BioPharma Surges as Loss Is Narrower Than Expected
The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2019
- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% -
Array BioPharma Announces 15.3 Months Median Overall Survival From The Safety Lead-in Of The Phase 3 BEACON CRC Trial Of The Combination BRAFTOVI®, MEKTOVI® And ERBITUX® In BRAF-Mutant Metastatic Colorectal Cancer
- Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium -
Array BioPharma To Present At The 37th Annual J.P. Morgan Healthcare Conference
BOULDER, Colo., Dec.
Interesting ARRY Put And Call Options For November 16th
Investors in Array BioPharma Inc. saw new options begin trading this week, for the November 16th expiration.
First Week Of ARRY March 2019 Options Trading
Investors in Array BioPharma Inc. saw new options begin trading this week, for the March 2019 expiration.
Strategies for 3 Biotechs Before FDA Action
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
Interesting ARRY Put And Call Options For December 21st
Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 21st expiration.
February Trade Ideas Rundown: How'd We Do?
A fresh look at all 17 ideas: the winners, the losers and the still to be determined.
